^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

NB002

i
Other names: NB002
Associations
Company:
Neologics Biosci
Drug class:
TIM-3 inhibitor
Associations
over1year
New P1 trial • Metastases
|
HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
NB002
over1year
NB002, a novel therapeutic antibody targeting unique epitope on TIM-3 presenting potent antitumor activity (AACR 2023)
These data could potentially explain novel features of NB002, restoring both acquired and innate immunity which could lead cold tumor to hot tumor.In summary, these data showed that NB002 is a potent anti-TIM-3 antibody with pre-clinical properties. A phase 1 study is planned and patients with advanced metastatic solid tumors will be recruited.
PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
|
HAVCR2 expression
|
NB002